RxDoctor Payments Data

Joseph Fan, MD

Ophthalmology · Monterey Park, CANPI 1508881715

Payments from drug & device makers

$22,676in general payments, 2019–2025

Across 254 payments — averaging $89.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$11K
  • AbbVie$6K
  • Genentech, Inc.$3K
  • Sun Pharmaceutical Industries Inc.$1K
  • Oyster Point Pharma, Inc.$509
  • Bausch & Lomb Americas Inc.$307
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,85592%
  • Education$2275%
  • Gifts$642%
  • Entertainment$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$22,676 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$829,065
Medicare patients
1,567
Services billed
7,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast1,009$968,786
RestasisCyclosporine1,065$963,705
Cyclosporine1,428$795,969
MieboPerfluorohexyloctane/Pf616$484,595
CequaCyclosporine163$133,687
LumiganBimatoprost157$54,748
TyrvayaVarenicline Tartrate79$52,916
Bepotastine Besilate264$50,971
RhopressaNetarsudil Mesylate122$47,735
Restasis MultidoseCyclosporine74$47,181
ZerviateCetirizine Hcl96$43,970
Alphagan PBrimonidine Tartrate100$37,160
Azelastine Hcl2,404$35,645
ProlensaBromfenac Sodium53$25,043
CombiganBrimonidine Tartrate/Timolol93$21,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$307$1,463,6441,651 claims
AbbVieRestasis, Lumigan, Restasis Multidose, Alphagan P, Combigan$5,524$1,124,5961,489 claims
Sun Pharmaceutical Industries Inc.Cequa$1,143$133,687163 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$172$68,813187 claims
Oyster Point Pharma, Inc.Tyrvaya$509$52,91679 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Bepreve, Besivance, Loteprednol Etabonate$175$49,865144 claims
Eyevance Pharmaceuticals LLCZerviate$90$43,97096 claims
AlconAzopt, Simbrinza$122$16,00151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →